Ventrus Poised For Run-Up Ahead Of Phase III Results
Jul. 14, 2014, 9:12 AM
- Ventrus Biosciences (NASDAQ:VTUS) shareholders approve the issuance of common stock for the merger with Assembly Pharmaceuticals. The transaction was effective at 5 pm on July 11, 2014. Ventrus shareholders also approved a 1-for-5 reverse stock split and the change of corporate name to Assembly Biosciences. It will begin trading under the symbol "ASMB" today.
Assembly Biosciences, Inc. operates as a biopharmaceutical company which develops novel treatments for hepatitis B virus infection and C. difficile-associated diarrhea. It specializes in the development of therapies for infectious diseases like HIV, CDAD and other disorders of the... More
Industry: Drug Manufacturers - Major
Country: United States
Other News & PR